Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg

Ernst, Corinna; Bejko, Dritan; Gaasch, Leo; Hannelas, Emilie; Kahn, Isaline; Pierron, Charlotte; Lero, Nesrine Del; Schalbar, Claude; Carmo, Elsa Do; Kohnen, Michel; Andlauer, Emmanuelle; Hublart, Pauline; Masi, Silvana; Garcia, Isabel de la Fuente; Vergison, Anne; Mossong, Joël

doi:10.2807/1560-7917.es.2024.29.4.2400033

articleEurosurveillanceJan 25, 2024DIAMOND OA

Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg

CECorinna Ernst DBDritan Bejko LGLeo Gaasch EHEmilie Hannelas IKIsaline Kahn

Luxembourg Institute of Health · European Centre for Disease Prevention and Control · +1 more institution

PubMed

Indexed incrossrefdoajpubmed

Abstract

After Luxembourg introduced nirsevimab immunisation against respiratory syncytial virus (RSV), estimated neonatal coverage was 84% (1,277 doses/1,524 births) in 2023. That year, paediatric RSV-related hospitalisations, especially concerning infants

Citation impact

129

total citations

FWCI: 45.42
Percentile: 100%
References: 9

Citations per year

Authors

16

Topics & keywords

Topics

Keywords

Medicine
Pediatrics
Palivizumab
Respiratory system
Neonatal intensive care unit
Paediatric intensive care unit
Pneumovirus
Virus

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.